Color gradient background for Myeloma Connect

Myeloma Connect

What are the key drivers for selecting ideal RRMM patients for treatment with CAR T-cell therapy?

16 November 2022 - 46 Minutes

Faculty

Michel Delforge

Joaquin Martinez-Lopez

Hermann Einsele

EM-93624

A focus on standard risk patients with MM and the roadmap to cure

15 November 2022 - 44 Minutes

Faculty

Mohamad Mohty

Jesús San Miguel

EM-93617

What are the key drivers for selecting ideal RRMM patients for treatment with bispecific antibodies?

25 October 2022 - 49 Minutes

Faculty

Michel Delforge

Paula Rodriguez Otero

Philippe Moreau

EM-93607

How do we ensure we choose the right treatment for the right patient?

4 October 2022 - 46 Minutes

Faculty

Mohamad Mohty

Faith Davies

Charlotte Pawlyn

EM-93604

MRD - What will change in the next year?

5 July 2022 - 45 Minutes

Faculty

Mohamad Mohty

Fredrik Schjesvold

EM-93560

Bispecific antibodies: raising new horizons for RRMM?

19 May 2022 - 47 Minutes

Faculty

María Victoria Mateos

Niels van de Donk

Ajai Chari

EM-88730

Practical considerations around CAR T-cell therapies for patients with multiple myeloma

12 May 2022 - 48 Minutes

Faculty

Michel Delforge

Paula Rodriguez Otero

Max Topp

EM-78417

Bridging the gap between patient and clinician perspectives in myeloma care

10 May 2022 - 46 Minutes

Faculty

Mohamad Mohty

Solène Clavreul

EM-78406

How do you plan the patient journey at diagnosis for patients with multiple myeloma?

28 April 2022 - 45 Minutes

Faculty

María Victoria Mateos

Philippe Moreau

Inger Nijhof

EM-78398

Is cure attainable in patients with multiple myeloma?

26 April 2022 - 45 Minutes

Faculty

Mohamad Mohty

Rakesh Popat

EM-78392

1
2